Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases

We report the discovery of a series of new drug leads that have potent activity against Mycobacterium tuberculosis as well as against other bacteria, fungi, and a malaria parasite. The compounds are analogues of the new tuberculosis (TB) drug SQ109 (1), which has been reported to act by inhibiting a transporter called MmpL3, involved in cell wall biosynthesis. We show that 1 and the new compounds also target enzymes involved in menaquinone biosynthesis and electron transport, inhibiting respiration and ATP biosynthesis, and are uncouplers, collapsing the pH gradient and membrane potential used to power transporters. The result of such multitarget inhibition is potent inhibition of TB cell growth, as well as very low rates of spontaneous drug resistance. Several targets are absent in humans but are present in other bacteria, as well as in malaria parasites, whose growth is also inhibited.

[1]  L. Silver,et al.  Multi-targeting by monotherapeutic antibacterials , 2007, Nature Reviews Drug Discovery.

[2]  E. Oldfield,et al.  Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis. , 1999, Biochemical and biophysical research communications.

[3]  Vinod Nair,et al.  SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis , 2012, Antimicrobial Agents and Chemotherapy.

[4]  G. Gale,et al.  EFFECT OF ETHAMBUTOL ON CYTOLOGY OF MYCOBACTERIUM SMEGMATIS , 1963, Journal of bacteriology.

[5]  R. B. Moon,et al.  Determination of intracellular pH by 31P magnetic resonance. , 1973, The Journal of biological chemistry.

[6]  M. Fischbach.  Combination therapies for combating antimicrobial resistance. , 2011, Current opinion in microbiology.

[7]  Gerry McDermott,et al.  Structural Basis of Multiple Drug-Binding Capacity of the AcrB Multidrug Efflux Pump , 2003, Science.

[8]  Daniel S. Palacios,et al.  Amphotericin primarily kills yeast by simply binding ergosterol , 2012, Proceedings of the National Academy of Sciences.

[9]  S. Cole,et al.  Simple Model for Testing Drugs against Nonreplicating Mycobacterium tuberculosis , 2010, Antimicrobial Agents and Chemotherapy.

[10]  M. Sternberg,et al.  Protein structure prediction on the Web: a case study using the Phyre server , 2009, Nature Protocols.

[11]  E. Oldfield,et al.  Tetra- to dodecanuclear oxomolybdate complexes with functionalized bisphosphonate ligands: activity in killing tumor cells. , 2010, Chemistry.

[12]  Fengping Wang,et al.  An uncultivated crenarchaeota contains functional bacteriochlorophyll a synthase , 2009, The ISME Journal.

[13]  N. Chim,et al.  Insights on how the Mycobacterium tuberculosis heme uptake pathway can be used as a drug target. , 2013, Future medicinal chemistry.

[14]  E. Oldfield,et al.  Lipophilic analogs of zoledronate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity , 2012, Proceedings of the National Academy of Sciences.

[15]  J. C. Hinshaw,et al.  Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non‐replicating persistence , 2009, Molecular microbiology.

[16]  Ping Chen,et al.  Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. , 2005, The Journal of antimicrobial chemotherapy.

[17]  R. Meganathan.  Biosynthesis of menaquinone (vitamin K2) and ubiquinone (coenzyme Q): a perspective on enzymatic mechanisms. , 2001, Vitamins and hormones.

[18]  E. Oldfield,et al.  Head-to-head prenyl tranferases: anti-infective drug targets. , 2012, Journal of medicinal chemistry.

[19]  K. Andries,et al.  Probing the Interaction of the Diarylquinoline TMC207 with Its Target Mycobacterial ATP Synthase , 2011, PloS one.

[20]  R. Moreno-Sánchez,et al.  Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs: study in mitochondria, submitochondrial particles, cells, and whole heart. , 1999, Biochemical pharmacology.

[21]  J. Richard Morphy,et al.  Designing multi-target drugs , 2012 .

[22]  R. Peek,et al.  In Vitro Characterization of the Anti-Bacterial Activity of SQ109 against Helicobacter pylori , 2013, PloS one.

[23]  A. Krogh,et al.  Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. , 2001, Journal of molecular biology.

[24]  E. Oldfield,et al.  Bisphosphonate inhibition of a Plasmodium farnesyl diphosphate synthase and a general method for predicting cell-based activity from enzyme data. , 2008, Journal of medicinal chemistry.

[25]  Paul W Smith,et al.  Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis , 2013, Science Translational Medicine.

[26]  K. Andries,et al.  Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. , 2012, Future microbiology.

[27]  W. S. Valdar,et al.  Scoring residue conservation , 2002, Proteins.

[28]  Michael S. Scherman,et al.  INHIBITION OF MYCOLIC ACID TRANSPORT ACROSS THE MYCOBACTERIUM TUBERCULOSIS PLASMA MEMBRANE , 2011, Nature chemical biology.

[29]  S. Krähenbühl,et al.  Mechanisms of hepatocellular toxicity associated with dronedarone--a comparison to amiodarone. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[30]  R. Wallace,,et al.  Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth , 1986, Journal of clinical microbiology.

[31]  S. Ogawa,et al.  High-resolution 31P nuclear magnetic resonance studies of metabolism in aerobic Escherichia coli cells. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[32]  N. Chim,et al.  The Mycobacterium tuberculosis Secreted Protein Rv0203 Transfers Heme to Membrane Proteins MmpL3 and MmpL11* , 2013, The Journal of Biological Chemistry.

[33]  A. Lupas,et al.  Evolutionary Relationships of Microbial Aromatic Prenyltransferases , 2011, PloS one.

[34]  I. Orme,et al.  Rapid Microbiologic and Pharmacologic Evaluation of Experimental Compounds against Mycobacterium tuberculosis , 2006, Antimicrobial Agents and Chemotherapy.

[35]  R. A. Nakashima,et al.  Studies on the mechanism of uncoupling by amine local anesthetics. Evidence for mitochondrial proton transport mediated by lipophilic ion pairs. , 1983, The Journal of biological chemistry.

[36]  D. Crick,et al.  MenA is a promising drug target for developing novel lead molecules to combat Mycobacterium tuberculosis. , 2009, Medicinal chemistry (Shariqah (United Arab Emirates)).

[37]  J. Sacchettini,et al.  MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212 , 2011, Antimicrobial Agents and Chemotherapy.

[38]  J. Richard Morphy.  Chapter 10:The Challenges of Multi-Target Lead Optimization , 2012 .

[39]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .

[40]  Terpene Biosynthesis: Modularity Rules , 2012 .

[41]  Ting-Kai Chang,et al.  Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation. , 2009, Journal of the American Chemical Society.